FDA approves AbbVie's Emblaveo for intra-abdominal infections, stock down in regular trading, up after-hours
From Nasdaq.: 2025-02-07 19:51:26 AbbVie has received FDA approval for Emblaveo, a new antibiotic for treating complicated intra-abdominal infections. The